Gary L. Davis
Teva Pharmaceuticals (United States) · 18 works · 684 citations · h-index 9
Top works
- Pathological diagnosis of chronic hepatitis C: A multicenter comparative study with chronic hepatitis B
- Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
- Prognostic and Therapeutic Implications of Extreme Serum Aminotransferase Elevation in Chronic Active Hepatitis
- Modeling therapeutic benefit in the midst of uncertainty
- A Psychometric Normative Database for Pre-Liver Transplantation Evaluations
- A Double-Blind, Placebo-Controlled Trial of the Effect of Chronically Administered Oral Acyclovir on Sperm Production in Men With Frequently Recurrent Genital Herpes
- Durability of viral response to interferon ribavirin combination in patients with chronic hepatitis C
- 1406 ALISPORIVIR (ALV) PLUS PEG-INTERFERON/RIBAVIRIN (PR) IN HCV G1 TREATMENT-EXPERIENCED PATIENTS ACHIEVES PRIMARY ENDPOINT WITH SUPERIOR EFFICACY AT TREATMENT WEEK 12 COMPARED TO RETREATMENT WITH PR
- Evaluating rapid virological response reduces ribavirin and peginterferon alfa-2B treatment costs for chronic hepatitis C in the United Kingdom
- 113 A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon-based therapy for chronic hepatitis C infection
- 1421 ALISPORIVIR (ALV) PLUS PEGINTERFERON/RIBAVIRIN (PR) ACHIEVES HIGH SVR12 RATES AMONG NULL RESPONDERS, IL28BCT/TT AND CIRRHOTIC HCVG1 PATIENTS (FUNDAMENTAL STUDY INTERIM ANALYSIS)
- Is peginterferon alfa-2B plus ribavirin cost-effective for treating chronic hepatitis C in the United Kingdom?
- Loss of HBsAg after interferon-α treatment: Cure of chronic hepatitis B virus?
- Interferon therapy for chronic hepatitis C
- Long-term safety, tolerability, and effectiveness of TV-46000 —a long-acting subcutaneous antipsychotic (lasca)—in patients with schizophrenia: the phase 3 shine study
- CA 67-Réponse virologique prolongée à l’albumine interféron alfa-2b en combinaison avec la ribavirine chez des malades non répondeurs à un traitement préalable par interféron et ribavirine : résultats intermédiaires d’une étude de phase 2